- KALM-1 study
- KALM-2 study
- KALM-1 and KALM-2 study pooled analysis
- Safety profile and tolerability
- Open-label safety study
- UKKW Expert panel: Real-World Evidence
- UKKW Expert panel: KDIGO Guidelines on IgAN
- UKKW Expert panel: Clinical Data
- Where are we with understanding itch in dialysis patients?
- Explore Iron Deficiency Anaemia and Chronic Kidney Disease (CKD) in the Paediatric patient
- Managing Iron Deficiency Anaemia in Oncology patients
- Explore pharmacy-led symptom management of patients on haemodialysis
- Explore real world evidence for KAPRUVIA® (difelikefalin)
- Understand the funding process for KAPRUVIA® (difelikefalin)
- Understand the clinical evidence for KAPRUVIA® (difelikefalin)
- Listen to experts discuss treatment pathways
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Fresenius Medical Care Renal Pharma, care of Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com.